InflaRxIFRX
IFRX
About: InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Employees: 74
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
8,650% more call options, than puts
Call options by funds: $175K | Put options by funds: $2K
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
4.02% more ownership
Funds ownership: 22.08% [Q4 2024] → 26.1% (+4.02%) [Q1 2025]
3% more funds holding
Funds holding: 30 [Q4 2024] → 31 (+1) [Q1 2025]
44% less capital invested
Capital invested by funds: $32.1M [Q4 2024] → $17.9M (-$14.2M) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
283%
upside
Avg. target
$7.75
889%
upside
High target
$10
1,176%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Oppenheimer Andreas Argyrides | 283%upside $3 | Outperform Maintained | 29 May 2025 |
Cantor Fitzgerald Steven Seedhouse | 1,176%upside $10 | Overweight Initiated | 29 Apr 2025 |
Guggenheim Yatin Suneja | 1,176%upside $10 | Buy Maintained | 26 Mar 2025 |
HC Wainwright & Co. Edward White | 920%upside $8 | Buy Reiterated | 21 Mar 2025 |
Financial journalist opinion
Based on 3 articles about IFRX published over the past 30 days
Negative
Benzinga
2 weeks ago
InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease
InflaRx N.V. IFRX on Wednesday announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG) recommended that the trial be stopped due to futility.
Neutral
GlobeNewsWire
2 weeks ago
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum
JENA, Germany, May 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG), recommended that the trial be stopped due to futility. This recommendation was based on data analysis of the first 30 patients enrolled in the study, with no unexpected adverse events noted by the IDMC. InflaRx as the study sponsor remains blinded to the study results.
Neutral
GlobeNewsWire
3 weeks ago
InflaRx to Participate in Upcoming Investor Conferences
JENA, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in multiple investor conferences in June and July 2025.
Neutral
GlobeNewsWire
1 month ago
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
JENA, Germany, May 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the three months ended March 31, 2025, and provided a business update.
Neutral
GlobeNewsWire
1 month ago
InflaRx to Report First Quarter 2025 Results on May 7, 2025
JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned.
Negative
Zacks Investment Research
2 months ago
InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
InflaRx (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Neutral
GlobeNewsWire
2 months ago
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
JENA, Germany, March 20, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the year ended December 31, 2024, highlighting recent operational achievements and expected milestones for 2025.
Neutral
GlobeNewsWire
3 months ago
InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
JENA, Germany, March 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of multiple posters describing the utility of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), including clinical efficacy data, safety assessments, and pharmacokinetic (PK) and pharmacodynamic (PD) analyses.
Neutral
GlobeNewsWire
3 months ago
InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all submitted abstracts, featuring the role of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), to be presented during the 2025 American Academy of Dermatology (AAD) Annual Meeting, March 7 - 11, in Orlando, FL.
Neutral
GlobeNewsWire
3 months ago
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences
JENA, Germany, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the fourth quarter and full year 2024 on March 20, 2025; no conference call is planned.
Charts implemented using Lightweight Charts™